IL156427A0 - Lentiviral vector-mediated gene transfer and uses thereof - Google Patents

Lentiviral vector-mediated gene transfer and uses thereof

Info

Publication number
IL156427A0
IL156427A0 IL15642701A IL15642701A IL156427A0 IL 156427 A0 IL156427 A0 IL 156427A0 IL 15642701 A IL15642701 A IL 15642701A IL 15642701 A IL15642701 A IL 15642701A IL 156427 A0 IL156427 A0 IL 156427A0
Authority
IL
Israel
Prior art keywords
gene transfer
lentiviral vector
mediated gene
mediated
lentiviral
Prior art date
Application number
IL15642701A
Other languages
English (en)
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of IL156427A0 publication Critical patent/IL156427A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15642701A 2000-12-19 2001-12-18 Lentiviral vector-mediated gene transfer and uses thereof IL156427A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25670100P 2000-12-19 2000-12-19
PCT/US2001/049241 WO2002049677A1 (en) 2000-12-19 2001-12-18 Lentiviral vector-mediated gene transfer and uses thereof

Publications (1)

Publication Number Publication Date
IL156427A0 true IL156427A0 (en) 2004-01-04

Family

ID=22973247

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15642701A IL156427A0 (en) 2000-12-19 2001-12-18 Lentiviral vector-mediated gene transfer and uses thereof
IL156427A IL156427A (en) 2000-12-19 2003-06-12 Use of a virulent vector containing an inhibitor of intraocular cell culture and intraocular vascular growth in the preparation of a drug that inhibits these

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156427A IL156427A (en) 2000-12-19 2003-06-12 Use of a virulent vector containing an inhibitor of intraocular cell culture and intraocular vascular growth in the preparation of a drug that inhibits these

Country Status (15)

Country Link
US (1) US20020114783A1 (ko)
EP (2) EP1343532B1 (ko)
JP (2) JP4280496B2 (ko)
KR (3) KR101026078B1 (ko)
CN (2) CN101732731B (ko)
AU (2) AU3405302A (ko)
CA (1) CA2432301C (ko)
DK (2) DK1343532T3 (ko)
ES (2) ES2422301T3 (ko)
IL (2) IL156427A0 (ko)
NZ (1) NZ526558A (ko)
PT (2) PT2301583E (ko)
RU (1) RU2288742C2 (ko)
WO (1) WO2002049677A1 (ko)
ZA (1) ZA200304664B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
AU3405302A (en) * 2000-12-19 2002-07-01 Res Dev Foundation Lentiviral vector-mediated gene transfer and uses thereof
EP1401480B1 (en) * 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization
WO2004028635A1 (en) * 2002-09-27 2004-04-08 Novartis Ag Ocular gene therapy
US7601341B2 (en) * 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
AU2004269233A1 (en) * 2003-08-29 2005-03-10 Kaneka Corporation Method of constructing transgenic bird using lentivirus vector and transgenic bird obtained thereby
CA2606989A1 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization
TW200824682A (en) * 2006-10-13 2008-06-16 Aqumen Biopharmaceuticals Kk Therapeutic and/or preventive agent for intraocular disorder comprising statin compound
CN101870734B (zh) * 2010-05-25 2012-06-20 北京大学 一种抑制新生血管生成的融合多肽及其编码基因与应用
RU2444734C1 (ru) * 2010-11-03 2012-03-10 ФГУ Ростовский НИИ акушерства и педиатрии Министерства по здравоохранению и социальному развитию РФ Способ прогнозирования невынашивания беременности ранних сроков инфекционного генеза
EP3110836A1 (en) 2014-02-25 2017-01-04 Research Development Foundation Sty peptides for inhibition of angiogenesis
WO2016073556A1 (en) * 2014-11-09 2016-05-12 The Trustees Of The University Of Pennsylvania Vision test for determining retinal disease progression
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
CN111398595A (zh) * 2020-02-17 2020-07-10 天津医科大学眼科医院 一种血浆小细胞外囊泡中的蛋白质tnfaip8的应用和检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969120A (en) * 1993-09-03 1999-10-19 Research Development Foundation Mutants of the RB and P53 genes
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
DE69733756T2 (de) * 1996-05-03 2006-06-01 Abbott Laboratories, Abbott Park Antiangiogenische peptiden, dafür kodierende polynukleotide und verfahren zur hemmung der angiogenesis
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
JPH1180024A (ja) * 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
AU3755900A (en) * 1999-03-15 2000-10-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU3405302A (en) * 2000-12-19 2002-07-01 Res Dev Foundation Lentiviral vector-mediated gene transfer and uses thereof

Also Published As

Publication number Publication date
CN100591359C (zh) 2010-02-24
EP1343532A4 (en) 2006-03-15
EP2301583B1 (en) 2012-08-22
AU3405302A (en) 2002-07-01
DK1343532T3 (da) 2013-07-29
RU2288742C2 (ru) 2006-12-10
EP1343532A1 (en) 2003-09-17
KR20080080684A (ko) 2008-09-04
CN101732731A (zh) 2010-06-16
ZA200304664B (en) 2007-02-28
KR20030075152A (ko) 2003-09-22
JP2004520307A (ja) 2004-07-08
EP2301583A1 (en) 2011-03-30
ES2422301T3 (es) 2013-09-10
WO2002049677A1 (en) 2002-06-27
CA2432301C (en) 2013-06-04
AU2002234053B2 (en) 2004-07-15
ES2393717T3 (es) 2012-12-27
KR20100011994A (ko) 2010-02-03
JP2009137998A (ja) 2009-06-25
CA2432301A1 (en) 2002-06-27
JP4280496B2 (ja) 2009-06-17
KR101026078B1 (ko) 2011-03-31
CN1487841A (zh) 2004-04-07
DK2301583T3 (da) 2012-12-10
IL156427A (en) 2011-06-30
NZ526558A (en) 2004-06-25
PT2301583E (pt) 2012-12-06
PT1343532E (pt) 2013-07-29
US20020114783A1 (en) 2002-08-22
CN101732731B (zh) 2013-04-10
EP1343532B1 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
AU3405302A (en) Lentiviral vector-mediated gene transfer and uses thereof
AU2002234053A1 (en) Lentiviral vector-mediated gene transfer and uses thereof
IL128193A0 (en) Rhamnosyl-transferase gene and uses thereof
GB0007651D0 (en) Gene sequence
IL153573A0 (en) Clk-2, cek-7 and coq-4 genes, and uses thereof
AU6424701A (en) Gasc1 gene
EP1293568A4 (en) PROTEIN AND ITS DNA
EP1241256A4 (en) NEW GENE AND USE
HUP0300813A3 (en) Genes and proteins, and their uses
EP1293510A4 (en) POLYPEPTIDE AND ITS DNA
EP1189920A4 (en) FAMILY OF GENES CAMELLO AND THE USE OF THE SAID GENES
GB0105922D0 (en) Genes and proteins, and their use
GB0003729D0 (en) Virulene gene and protein, and their use
GB0123170D0 (en) Genes,proteins,and their use
GB9908171D0 (en) Gene and use thereof
EP1300467A4 (en) NEW POLYPEPTIDE AND CORRESPONDING DNA
GB0026351D0 (en) Nucleotide sequences and uses thereof
GB0026350D0 (en) Nucleotide sequences and uses thereof
GB0003731D0 (en) Virulence gene and protein, and their use
GB0003730D0 (en) Virulence gene and protein, and their use
GB0002552D0 (en) Virulence gene and protein, and their use
GB0003732D0 (en) Virulence gene and protein, and their use
GB0003733D0 (en) Virulence gene and protein, and their use
GB0003735D0 (en) Virulence gene and protein, and their use
GB0010585D0 (en) Virulence gene and protein, and their use